Stimulation of platelet production: the new treatment approach to chronic immune thrombocytopenic purpura
https://doi.org/10.17650/1818-8346-2009-0-1-51-5
Abstract
Chronic immune thrombocytopenic purpura (ITP) is one of the most frequent immune hematological disorders in which development the leading part is played by the antibodies directed against a narrow spectrum of platelet antigens. Though death rate at chronic ITP is insignificant, no more than 1%; disease strongly reduces patients quality of a life, and frequently requires difficult and expensive treatment. Antiplatelets antibodies mediating ITP, are directed against glycoprotein GP IIb/IIIa and, less often, GP Ib/IX. At ITP can be registered both raised bone marrow platelet production and accelerated peripheral blood platelet clearance, and strongly decreased production and normal platelet life-span. Antibodies to platelet membrane glycoproteins directly disturb platelet production in bone marrow. Standard drug interventions at chronic ITP - glucocorticoids in various doses, high doses intravenous immunoglobulin, anti-D immunoglobulin, rituximab - rare lead to stable increase platelet number while in 2/3 patients splenectomy is effective. The new therapy approach in chronic ITP is stimulation of platelet production in bone marrow. Recombinant fusion protein Romiplostim stimulates trombopoietin receptor and it is effective at long-term therapy in 87% patients with chronic ITP irrespective of previous splenectomy. TPO antibodies development with romiplostim therapy was not revealed.
About the Authors
A. A. Maschan
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
A. G. Rumyantsev
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Moscow
References
1. Frederiksen H., Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909—13.
2. Donato H., PicЧn A., Martinez M. et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: A multicentered study from Argentina. Pediatr Blood Cancer 2008;52(4):491—6.
3. Godeau B., Provan D., Bussel J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007;14(5):535—56.
4. Harrington W.J., Minnich V., Hollingsworth J.W. et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1—10.
5. Hamidpour M., Behrendt M., Griffiths B. et al. The isolation and characterization of antiplatelet antibodies. Eur J Haematol 2006;76(4):331—8.
6. McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol 2003;25(Suppl 1):57—61.
7. Fischer P., Jendreyko N., Hoffmann M. et al. Platelet reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia. Br J Haematol 1999;105:626—40.
8. Roark J.H., Bussel J.B., Cines D.B. et al. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002;100:1388—98.
9. Kuwana M., Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol 2005;81(2):106—12.
10. Kuwana M., Kaburaki J., Kitasato H. et al. Immunodominant epitopes on glycoprotein IIb—IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001;98:130—9.
11. Filion M.C., Proulx C., Bradley A.J. et al. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow derived cells. Blood 1996;88:2144—50.
12. Webster M.L., Sayeh E., Crow M. et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIalpha versus GPIb alpha antibodies. Blood 2006;108(3):943—6.
13. Siegel R.S., Rae J.L., Barth S. et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989;30:206—12.
14. Louwes H., Zeinali Lathori O.A., Vellenga E. et al. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 1999;106:430—4.
15. Chang M., Nakagawa P.A., Williams S.A. et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102(3):887—95.
16. McMillan R., Wang L., Tomer A. et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103(4):1364—9.
17. Stasi R., Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clinic Proc 2004;79:504—22
18. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science NY 2001;291:484—6.
19. Legouffe E., Hulin C., Grange M.J. et al. French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359(9300):23—9.
20. Mazzucconi M.G., Fazi P., Bernasconi S. et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007;109:1401—7.
21. Scaradavou A., Woo B., Woloski B.M. et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689—700.
22. Newman G.C., Novoa M.V., Fodero E.M. et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001;112:1076—8.
23. Kojouri K., Vesely S.K., Terrell D.R. et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623—34.
24. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric antiCD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98(4):952—7.
25. Godeau B., Porcher R., Fain O. et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112(4):999—1004.
26. Li J., Yang C., XiaY. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241—8.
27. Nichol J.L. AMG 531: an investigational thrombopoiesis-stimulating peptibody. Pediatr Blood Cancer 2006;47 (5 Suppl):723—5.
28. Newland A., Caulier M.T., KappersKlunne M. et al. An open-label, unit dosefinding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006;135(4):547—53.
29. Bussel J.B., Kuter D.J., Pullarkat V. et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2008, Nov 3. [Epub ahead of print]
30. Bussel J.B., Cheng G., Saleh M. et al. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebo controlled trial of eltrombopag, an oral platelet growth factor. Blood 2006;108:Abstr 475.
31. Bussel J., Provan A., Shamsi T. et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study. Haematologica 2007;92(Suppl 1):Abstr 1814.
Review
For citations:
Maschan A.A., Rumyantsev A.G. Stimulation of platelet production: the new treatment approach to chronic immune thrombocytopenic purpura. Oncohematology. 2009;(1):51-56. (In Russ.) https://doi.org/10.17650/1818-8346-2009-0-1-51-5
Views:
456
Email this article 